Biotech

All Articles

TPG tops up funds to $580M for assets all over lifestyle sciences

.Resource manager TPG, which has actually assisted biotechs such as Sionna Therapeutics and also San...

Merck quits period 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has experienced yet another trouble. Months after shuttering a period...

After a difficult year, Exscientia folds up in to Recursion

.After a year defined by pipe cuts, the shift of its CEO and discharges, Exscientia is going to merg...

Cullinan, after $25M offer, hands back bispecific to Harbour

.Cullinan Therapeutics was actually wowed enough with Port BioMed's bispecific immune activator that...

A better check out Strong Biotech's Tough 15

.Within this week's incident of "The Top Line," we're diving into Fierce Biotech's annual Fierce 15 ...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's event celebrating the commendation o...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of notable management hirings, shootings and als...

Lykos will certainly inquire FDA to reevaluate its decision complying with rejection of MDMA treatment for trauma

.Following an inadequate presenting for Lykos Therapies' MDMA candidate for trauma at a current FDA ...

AN 2 halves headcount, quits period 3 test after information let down

.AN2 Rehabs is reconsidering its own organization in reaction to uninspired midphase records, vowing...

Merck pays for $700M for bispecific, snooping autoimmune opening as well as possibility to test Amgen in cancer cells

.Merck &amp Co. is paying out $700 thousand upfront to challenge Amgen in a blood stream cancer cell...